Background--We investigated the hypothesis that the favorable effects of gastrointestinal (GI) intervention on hypertension (HTN) and cardiovascular (CV) disturbances are mediated by antagonizing overdrive of the sympathetic nervous system (SNS).
T he autonomic nervous system (ANS), including the sympathetic nervous system (SNS) and parasympathetic nervous system, is a collection of afferent and efferent neurons that link the central nervous system (CNS) with visceral effectors. The neural control of the circulation operates through parasympathetic neurons that innervate the heart and sympathetic efferent neurons that innervate blood vessels, heart, kidneys, and the adrenal medulla. 1, 2 The sympathetic nerves dominantly regulate cardiovascular (CV) structure and function by promoting the release of adrenal catecholamine and activation of the renin-angiotensin-aldosterone system. 3 It is well known that activation of the SNS contributes to the development of hypertension (HTN) as well as CV remodeling and dysfunction. [4] [5] [6] [7] [8] Currently, adrenergic receptor blockers, renal sympathetic nerve denervation (RSND), and electric stimulation of the carotid sinus are used to treat HTN and its complications. [9] [10] [11] However, little attention is given to the effect of gastrointestinal (GI) intervention to autonomic nerves, especially GI nerve innervation, on CV regulation. Bariatric surgery, also called metabolic surgery, can induce substantial and sustained weight loss and is a highly effective treatment for severe obesity and diabetes. [12] [13] [14] A substantial number of clinical and experimental studies have shown that GI intervention also resolved HTN and improved the prognosis of CV events (CVEs). [15] [16] [17] [18] [19] [20] Interestingly, the improvement in high blood pressure (BP) occurs before any appreciable weight loss after metabolic surgery. 17 The precise mechanisms underlying the resolution of HTN after metabolic surgery have not been determined, although several mechanisms, such as metabolic surgery-induced weight loss, changes in gut hormones, and increased urinary sodium excretion, have been postulated. [20] [21] [22] It has recently been reported that metabolic surgery resulted in a significant reduction in heart rate (HR) and an enhancement in HR recovery. 15, 23 Subjects who had undergone gastric bypass had significantly lower muscle sympathetic nerve activity, compared to obese subjects. 24 These studies suggest that metabolic surgery had an impact on visceral SNS. Therefore, we hypothesized that the beneficial effect of metabolic surgery on HTN may stem from inhibition of sympathetic nerve activity. In this study, we showed that GI intervention resolved HTN and improved CV disturbances by antagonizing the activation of the SNS, independent of weight loss, in both diabetic hypertensive patients and genetic hypertensive rats.
Methods Patient Study
All studies were performed according to the principles of the Declaration of Helsinki. The institute's ethics committee of Daping Hospital approved the study. Ten male and 11 female hypertensive patients with type 2 diabetes (T2DM) were recruited (mean age, 45.2AE10.4 years). Subjects were classified by the following criteria: (1) HTN, BP ≥140/90 mm Hg, or treated HTN; (2) diabetes, fasting plasma glucose (FPG) ≥7.0 mmol/L, and/or oral glucose tolerance test (OGTT; 2 hours ≥11.1 mmol/L), or treated diabetes; and (3) obesity, body mass index (BMI) ≥28 kg/m 2 or waist circumference (WC) higher than 90 cm in men or 85 cm in women. 25 The bariatric surgery indication for Chinese T2DM is: (1) BMI ≥35 kg/m 2 , T2DM with or without complications, should be considered for GI metabolic surgery; (2) BMI 30 to 35 kg/m 2 , T2DM, if difficult to control blood glucose or complications, especially CV risk, by lifestyle changes and drug therapy, GI metabolic surgery should be one of the treatment choices; (3) BMI 28.0 to 29.9 kg/m 2 , T2DM with central obesity (WC >85 cm for female and >90 cm for male) and at least another 2 criteria of metabolic syndrome (high triglycerides [TGs], low high-density lipoprotein cholesterol [HDL-C] levels, or high BP). For these patients, GI metabolic surgery may be considered for the treatment of choice; and (4) BMI 25.0 to 27.9 kg/m 2 , patients with T2DM should be informed consent and in strict accord with research programs. However, these procedures should be considered only as a pure clinical research preceding approval of the ethics committee, and not a wide recommendation. 26 All patients were recruited in our hospital, and the time frame for patient recruitment was from November 2011 to July 2013 and they received laparoscopic Roux-en-Y gastric bypass (RYGB). 27 All patients were informed of the risks and benefits of each procedure and provided written, informed consent. All patients underwent complete evaluation before and after the metabolic operation and then were followed up at 1, 3, 6, and 12 months. Some measurements were duplicated, including 24-hour ambulatory BP, flow-mediated dilation (FMD), anthropometric and clinical parameters, as well as blood glucose and lipids.
Anthropometry Assessments
A general physical examination was conducted at each visit at the same time of day, with the participant wearing light clothing and no shoes. All procedures were performed by the same examiner using the same calibrated scale. WC was measured using a nonelastic tape at the midpoint between the bottom of the rib cage and the top of the iliac crest at minimal respiration to the nearest 0.1 cm. Height (m) was recorded to the nearest 0.1 cm on a portable standiometer, and weight was measured to the nearest 0.1 kg with the patient standing motionless in the center of the scale after adjustment for the estimated weight of clothing. BMI was calculated as weight/height 2 .
Human BP Monitoring
Ambulatory blood pressure monitoring (ABPM) was performed with a Spacelabs 90207 (Spacelabs Medical, Issaqua, WV) at baseline and at 6 months. The cuff size was adjusted to the upper-arm circumference. ABPM measurements were performed every 15 minutes during the daytime and every 20 to 30 minutes at night. ABPM profiles were divided into daytime (8:00 AM to 8:00 PM) and nighttime periods (12:00 AM to 6:00 AM). 28 Office BP was measured by a physician using a mercury sphygmomanometer after the participant had rested at least 5 minutes in the sitting position. First and fifth phases of Korotkoff sounds were taken as systolic blood pressure (SBP) and diastolic blood pressure (DBP), respectively. Three measurements were taken at 2-minute intervals and recorded, and the average was used to define the SBP and DBP.
fossa before inflation of a pneumatic cuff on the upper arm to 250 mm Hg for 5 minutes and at 1 minute after cuff release. FMD was expressed as percentage dilation from the baseline diameter to that observed 1 minute after cuff release.
Laboratory Measurements
After an overnight fast, laboratory tests were obtained for measurement of FPG, OGTT (2 hour), plasma insulin, glycated hemoglobin (HbA1C), high-sensitivity C-reactive protein (hs-CRP), total cholesterol (TC), TGs, HDL-C, and low-density lipoprotein cholesterol (LDL-C). Oral glucose tolerance (2-hour) was tested during an OGTT (75-g glucose load). Fasting blood samples were collected in EDTA and assayed for hs-CRP by a validated high-sensitivity assay using turbidimetric immunoassay (Orion Diagnostica, Espoo, Finland). Samples were stored frozen at À70°C until analysis. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated on the basis of FPG and serum insulin levels. 27 
Animal Treatments
Eight-week-old male spontaneously hypertensive rats (SHRs) were obtained from Charles River Laboratories (Bar Harbor, ME). Rats were housed under a 12-hour day/night cycle with free access to food and water. The institute's animal care and use committee approved all animal protocols. Rats were randomly assigned to either the RYGB (surgery) or sham surgery group (sham). A subgroup of sham SHRs was restricted and consumed 30% less chow than other sham SHRs. There were 12 animals in each group. The animal study protocol is shown in Figure 1A . The 24-hour urine sample was collected in metabolic cages to measure urinary sodium excretion.
Animal BP Measurements
SHRs were surgically implanted with telemetric transmitters (TA11PA-C40; Data Sciences International, Saint Paul, MN) before metabolic surgery. The catheter portion of the implant was placed into the distal portion of the descending aorta. Rats were allowed to recover from surgery for 7 days, and then 24-hour SBP, DBP, and HR were measured by telemetry in conscious and unrestrained rats at week 0 (baseline) and week 12 after surgery. BP and HR were recorded weekly for 1 hour at 10:00 AM. We collected data for 10 seconds every minute and used the mean values for statistical analysis. 30 
Metabolic Surgery and Postoperative Care of SHRs
RYGB is the most common type of metabolic surgery. After surgical implantation of the telemetric transmitters, SHR rats were allowed to recover for 1 week and then RYGB was performed, as previously reported. 31 After overnight food deprivation, rats were deeply anesthetized with isoflurane (4% induction, 1.5% maintenance; VIP-3000 Vaporizer; Matrix, Orchard Park, NY) 32 and abdominal organs exposed by laparotomy. First, a gastric pouch of %10% of the total stomach volume was formed using scissors, and the distal cut end of the stomach was sutured. Second, the jejunum was transected %10 cm from the ligament of Treitz, and the distal cut end was anastomosed to the gastric pouch. Third, the proximal cut end of the jejunum was anastomosed to the side of the lower jejunum (%20 cm from the ligament of Treitz). For sham surgery, transections of the GI tract were performed at all sites where enterotomies were performed for the RYGB, but were reanastomosed to maintain the physiological circuit of food through the bowel. On the day after surgery, rats were given access to a limited amount of Ensure. Three days after surgery, rats were fed ad libitum with normal chow. Two rats (16.7%) in the RYGB group and 1 (8.3%) in the sham surgery group died of complications during the operation or within the first 24 hours after surgery.
Cold Exposure-Induced BP and HR Variability of SHRs
SHRs were subjected to a periodic change of ambient temperature at week 12. The rhythm of the temperature fluctuation was as follows. A starting temperature of 26°C was ramped downward over 10 minutes to reach 4°C and was held there for 5 minutes. The temperature was then ramped upward over 10 minutes to reach 26°C and was held there for 5 minutes. Another 30-minute cycle was then started. The temperature settings were in accord with previous studies. 33, 34 All rats underwent 3 cycles, changes of SBP, DBP, and HR were measured with the telemetry system, and variations in those parameters were calculated as the difference between highest and lowest values in every cycle.
Echocardiography of SHRs
Echocardiography was performed with the VisualSonics Vevo 770 imaging system (VisualSonics Inc., Toronto, Ontario, Canada) using a 710 scan head in animals anesthetized with isoflurane, as mentioned above, after 20 weeks, as previously reported. 35 The left ventricle internal diameter (LVID), interventricular septum thickness (IVST), and left ventricular posterior wall (LVPW) were measured in the short-axis view from M-mode recordings in end diastole and end systole. The peak early diastolic filling velocity (E wave) and peak late diastolic filling velocity (A wave) were taken using the apical 4-chamber view. 
Microinjection of the Nucleus of the Solitary Tract
Animals were placed in a stereotaxic apparatus, and a partial craniotomy of the occipital bone was performed. The dorsal surface of the brainstem was exposed. The coordinates for the nucleus of the solitary tract (NTS) were determined from the atlas, which were 0.5 mm rostral to the caudal tip of the area postrema, 0.5 mm lateral to the midline, and 0.5 mm below the dorsal surface of the brain stem. After baseline mean arterial blood pressure (MAP) and HR recording, microinjections of gamma-aminobutyric acid (GABA; 0.1, 1, and 10 nmol/L) into the NTS were made with glass pipettes (tip size, 20 to 40 lm) coupled to a pressure injection apparatus (PicoPump; World Precision Instruments, Sarasota, FL). The volume of injection (60 nL) was estimated from displacement of the fluid meniscus in the pipette using a calibrated reticule. Microinjection sites were marked with 2% pontamine sky blue.
Measurement of Plasma Glucagon-Like Peptide 1
Plasma was kept from RYGB and sham SHRs. Plasma glucagon-like peptide 1 (GLP-1) levels were assayed by the Glucagon-Like Peptide-1 (Active) ELISA kit (Linco Research, Inc., Saint Charles, MO), according to the manufacturer's instructions.
Urinary Sodium Excretion Measurement
SHRs were acclimatized to the metabolic cages (Techniplast 3701M001; Tecniplast Gazzada S.a r.l., Buguggiate, Italy) for 48 hours, then 24-hour urine was collected through metabolic cages to measure urinary sodium excretion.
Renal Sympathetic Nervous Activity and Baroreflex Analysis of SHRs
Renal sympathetic nervous activity (RSNA) and baroreflex were analyzed after 20 weeks, as previously reported. 36 Briefly, rats were anesthetized with pentobarbital sodium (45 mg/kg, IP), and the trachea was cannulated to facilitate mechanical respiration. The femoral artery was catheterized for BP measurement. HR was derived from the BP pulse by a PowerLab Chart system (ADInstruments, Dunedin, New Zealand). The femoral vein was cannulated for intravenous injections. Body temperature was kept at 37°C by a temperature controller. The left renal sympathetic nerves were exposed, identified, and dissected free of the surrounding connective tissue and then a pair of recording electrodes were attached to the nerves. Pressor doses of phenylephrine (10 lg/kg, IV; Sigma-Aldrich, St. Louis, MO)
were acutely administered to induce reflex bradycardia. Both the nerve and the electrodes were covered with a fastsetting silicone (Wacker Sil-Gel, Wacker Chemie AG, Munich, Germany). The signal was amplified (bandpass, 100 to 3000 Hz) with a preamplifier (FZG-81; Shanghai Institute of Physiology, Shanghai, China). The distal terminal of the renal nerve was cut to avoid afferent activity. The baseline RSNA represented 100% (after subtraction of the background noise level from the absolute value). Arterial baroreflex was evaluated by the mean index relating changes in RSNA to changes in MAP and expressed as mVs per mm Hg.
Vascular Constriction Measurement of SHRs
Endothelium-dependent vascular constriction of freshly isolated arteries was studied using a myograph system (Danish Myo Technology A/S, Aarhus, Denmark), as previously described. 30, 37 After rats were anesthetized with pentobarbital 
4).
After measurement of the passive-tension internal circumference characteristics, the tension was set to the estimated in vivo internal circumference. After a 60-minute stabilization period, the functional integrity of the rings was confirmed by contraction in response to KCl (60 mmol/L). The presence of endothelium was confirmed by a relaxant response to acetylcholine (Ach; 1 mmol/L) in rings that had been contracted by exposure to phenylephrine (PE; 1 mmol/L). Segments relaxing >80% were considered being endothelium intact, whereas those relaxing <5% were defined as being endothelium denuded. PE and Ach were purchased from Sigma-Aldrich. Vasoconstriction induced by perivascular nerve stimulation was measured by electrical field stimulation (EFS) using a stimulator (SD9 Grass Stimulator; Natus Neurology Incorporated, Grass Products, Warwick, RI) connected to 2 platinum electrodes placed on each side of the vessel parallel to its longitudinal axis. Frequency-response curves to EFS (2, 4, 8, 16, 32 , and 64 Hz) were performed. The parameters used for EFS were 200 mA, 0.3 ms, and 2 to 64 Hz for 30 seconds with an interval of 1 minute between each stimulus, which was the time required to recover basal tone. In every experiment, the first frequency-response curve served as the control and the time between the first and second frequency-response curve was 60 minutes. EFSinduced contractions and concentration-response curves in response to noradrenaline treatment were obtained from separate preparations.
Histopathological Examination
After 20 weeks, samples were processed as previously described. 38 Frozen sections of heart ventricles and mesenteric arteries (10 lm) were obtained and stained with hematoxylin-eosin (H&E) or with Masson's trichrome reagent for measurement of collagen deposition. Microscopic visualization and photographs were obtained, and the measurements were performed by a blinded investigator using NIS-Elements 3.2 software (Nikon, Tokyo, Japan). 
Statistical Analysis

Results
Metabolic Surgery Lowered BP in Genetic Hypertensive Rats
In this study, we used SHRs, an established animal model of genetic HTN. After surgical implantation of the telemetric transmitters, SHR rats were allowed to recover for 1 week and then RYGB was performed ( Figure 1A and 1B). Radiotelemetry showed that metabolic surgery significantly reduced BP, and these hypotensive effects were maintained for an extended period of time ( Figure 1C) . Furthermore, 24-hour BP was significantly lowered in SHRs with surgery, compared to sham SHRs and SHRs before surgery (Figure 1D ). These data indicate that metabolic surgery reduced BP in genetic hypertensive rats in the absence of metabolic disturbances.
Metabolic Surgery Improved Vascular Remodeling and Dysfunction
After surgical treatment for 20 weeks, mesenteric and femoral arteries were isolated from SHRs. In SHRs with surgery, H&E staining showed larger lumen diameters and thinner walls, as determined by the lower wall-to-lumen ratio, compared to sham SHRs (Figure 2A ). Endothelial-dependent relaxations were also improved in mesenteric and femoral arteries from SHRs with surgery, compared to sham SHRs ( Figure 2B ). These results suggest that the reduction in BP was related to the improvement of vascular relaxation.
Metabolic Surgery Reserved Cardiac Hypertrophy and Dysfunction
To further examine the effect of metabolic surgery on cardiac structure and function, hearts were isolated from SHRs and stained as described above. Heart weight, the ratio of heart weight to body weight, and myocardial collagen volume fraction were significantly reduced in SHRs with surgery, compared to sham SHR ( Figure 3A and 3B). M-mode echocardiography images analysis showed that SHRs with surgery had larger LVID, lower IVST, and LVPW thickness, as well as decreased mitral valve E/A ratio, compared to sham SHRs ( Figure 3C and 3D) . These results suggest that metabolic surgery also improves cardiac remodeling and dysfunction.
Metabolic Surgery Antagonized Overdrive of SNS
The question remained as to what mechanism involved in metabolic surgery could mediate the improvement of CV disturbances. It is well known that SNS overdrive plays an important role in the development of HTN and CV disorders. Compared to sham SHR, we found a time-related reduction in HR in SHRs with surgery, which was validated by the 24-hour ambulatory BP monitoring ( Figure 4A ). To further confirm the role of SNS, SHRs were exposed to cold stress in a temperature-controlled chamber. A larger variability of BP and HR was observed in sham SHRs, but not in SHRs with surgery ( Figure 4B ). Our results indicated that SNS overdrive in SHRs can be antagonized by metabolic surgery through inhibition of both peripheral and central sympathetic nerve activity.
Effect of Metabolic Surgery on Peripheral and Central Sympathetic Nerve Activity
To examine the effects of metabolic surgery on sympathetic outflow in SHRs, RSNA and baroreflex sensitivity were measured after intravenous injection of PE in anesthetized rats. As shown in Figure 5A , the basal RSNA was lower in SHRs with surgery, compared to sham SHR. After bolus injections of PE, the increasing BP resulted in a profound bradycardia and sympathetic inhibition in SHRs with surgery ( Figure 5A ). Stimulating the perivascular nerve by EFS can induce a vasoconstriction. We found that EFS induced a frequency-dependent contractile response, which was significantly lower in isolated vascular segments from SHRs with surgery, compared to sham SHR ( Figure 5B ). Furthermore, microinjection of GABA into the NTS significantly reduced changes of artery BP in SHRs with surgery, compared to sham SHR. These indicated that GI intervention may be an effective treatment of HTN through inhibition both peripheral and central sympathetic nerve activity ( Figure 5C and 5D ). In addition, SHRs with surgery reduced food intake and body weight ( Figure 6A and 6B), but had a similar sodium intake and 24-hour urinary sodium level, compared to sham SHR ( Figure 6C ). However, plasma GLP-1 concentration was significantly higher in SHRs with surgery, compared to sham SHR ( Figure 6D ). In order to rule out the effect of weight loss on BP and SNS, 1 subgroup of sham SHRs was restricted with food intake for 4 weeks to approach the same body weight as SHRs with surgery. Interestingly, there were no significantly differences in BP, HR, and RSNA between sham SHRs with and without dietary restriction ( Figure 6E ). These results strongly support that the effect of GI intervention on BP is independent of weight loss.
Effect of Metabolic Surgery on BP in Diabetic Hypertensive Patients
As a proof of principle, we further evaluated whether metabolic surgery lowers BP and improves vascular function through inhibition of SNS in human HTN with T2DM. Compared with presurgery levels, there was a reduced BP in hypertensive patients underwent metabolic surgery (Figure 7A) . Additionally, the endothelium-dependent vasodilatation was significantly improved in hypertensive patients underwent metabolic surgery after the third month (Figure 7B) . ABPM further confirmed a reduction in BP after metabolic surgery ( Figure 7C ). Furthermore, metabolic surgery significantly reduced the kinds and dosage of antihypertensive drugs taken by hypertensive patients ( Figure 7D ). Consistent with the findings in SHRs, hypertensive patients also showed a time-dependent reduction in HR after surgery, especially in the daytime, which was significantly correlated with reduction in BP ( Figure 7E ). In addition, waist circumstance, body weight, BMI blood lipid and glucose levels were significantly improved in hypertensive patients with T2DM ( Figure 7F ; Table) . These results suggest that metabolic surgery can lower BP and ameliorate vascular dysfunction in hypertensive patients with comorbid metabolic disorders that might antagonize the overdrive of SNS (Figure 8) . 
Discussion
The present study provides evidences for the beneficial effect of metabolic surgery on HTN and cardiac-metabolic risks. Our studies confirmed that GI surgical intervention can significantly inhibit the overdrive of SNS 24 in genetic hypertensive rats, which results in reducing BP and improvement of CV remodeling and dysfunction. In addition, metabolic surgery inhibited RSNA and the peripheral vascular nerve induced vasoconstriction as well as central baroreflex in these hypertensive rats. Importantly, this beneficial effect of metabolic surgery was also shown in hypertensive patients with T2DM. Furthermore, metabolic surgery reduced HR in a time-dependent manner in hypertensive patients. Taken together, we propose a mechanism by which metabolic surgery ameliorates HTN and cardiac/metabolic disturbances by antagonizing SNS activation. Metabolic surgery is currently the most effective treatment option for obesity and diabetes. [12] [13] [14] In addition, metabolic surgery can effectively ameliorate HTN over the long term and reduce future CVEs [15] [16] [17] [18] [19] [20] ; however, the underlying mechanisms remain elusive. Several studies suggest that the reduction in BP could be related to metabolic surgery-induced weight loss. 39, 40 However, clinical trials and experimental studies indicated that a quick reduction in BP occurred before the metabolic surgery-mediated weight loss. 17 A meta-analysis reported that there was resolution of HTN in 61.7% of patients and resolution or improvement of HTN in 78.5% of patients after metabolic surgery. 14 Antihypertensive therapy was reduced or discontinued in 70% of patients receiving metabolic surgery. 41 We also showed that the beneficial effect of metabolic surgery on BP was independent of weight loss in surgically treated hypertensive rats and was independent of surgical trauma and food intake. 15, 18 However, the mechanism underlying the metabolic surgery-mediated antihypertensive effect remains unknown. Although the precise mechanisms mediating HTN remission after metabolic surgery remains poorly understood, it is apparent that rearrangements of GI anatomy can exert several discrete antihypertensive effects beyond those related to reduce sodium intake and body weight. Proposed multiple factors include the changes in gut hormones, insulin sensitivity, GI nerve innervation, and intestinal microbial flora. 37, [42] [43] [44] [45] [46] [47] Antagonizing the SNS by metabolic surgery could be one of the factors responsible for hypotension. It is well known that overdrive of SNS contributes to the pathogenesis of HTN and cardiometabolic disease. [4] [5] [6] [7] [8] Administration of aor b-adrenergic blockers or clonidine, a drug that stimulates central a2-receptors and reduces SNS activity, can prevent high-fat-diet-induced HTN in obese dogs. Combined a-and b-adrenergic blocker treatment reduced ambulatory BP more in obese hypertensive patients than in lean hypertensive patients. 48 In this study, metabolic surgery reduced HR in both hypertensive patients and rats in a time-dependent manner. Furthermore, variations in BP and HR under cold exposure were strikingly smaller in the surgically treated hypertensive rats than that in sham hypertensive rats. These findings suggest that the metabolic surgery-mediated hypotension was closely associated with the inhibition of overdrive of the SNS. It is well documented that renal sympathetic nerves mediate most of the chronic effects of SNS activation on BP. 49 In addition, the impact of GI autonomic nerves on BP is well recognized. One early study reported that an appropriate amount of electrical stimulation of the central cut end of the abdominal vagus raised BP by 30 mm Hg. 50 HTN is referred to as neurogenic if it is the result of abnormal stimulation of the ANS, rather than the result of a primary vascular or renal defect. This abnormality can originate in the afferent arm of the system or in the central circuitry. The level of nucleus activity at rest is presumed to be the most crucial parameter for long-term BP control. 10 This neural activity is set by a core network of neurons that reside in the rostral ventrolateral medulla, the spinal cord, the hypothalamus, and the NTS. 10 Recent studies show that dietary factors, gut flora, and hormones can affect the nervous system through a gut-brain cross-talk. 42, 51, 52 Endogenous GI noradrenalin is being released, especially in the duodenum, where the concentration of noradrenalin is the highest. 53 Sensory stimulation in the GI tract is involved in the regulation of the SNS through the CNS. 52 A recent study reported that there was a vagal remodeling and denervation of the stomach and part of intestine following metabolic surgery. 54 In addition to hormones and circulating factors, the gut communicates with the brain through primary visceral afferent nerve fibers, such as GI or renal nerves, comprised in the vagus and the dorsal root/ spinal cord pathway. 55 Thus, metabolic surgery alters existing gut-brain communication and results in an alteration of the neural control of the target organs, such as the heart, blood vessels, and kidney. In this study, we showed that RSNA and vasoconstriction by perivascular nerve stimulation were significantly inhibited in surgically treated hypertensive rats, compared to sham hypertensive rats. To further identify which specific circuit or reflex pathway or cerebral nucleus is affected, the effect of metabolic surgery on the central baroreflex pathway was examined. The NTS is a termination site for primary afferent fibers from baroreceptors, and other peripheral CV receptors, that contain BP-sensitive neurons.
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GABA is a well-known neurotransmitter that exerts inhibitory actions in the brain, mediated through its receptors. [56] [57] [58] We showed that microinjection of GABA into the NTS caused smaller changes of BP in SHRs with surgery, compared to sham SHRs. These striking results indicate that GI intervention may be an effective method for treatment of HTN through inhibition of both peripheral and central sympathetic nerve activity.
Although the reduction of renal sympathetic afferent and efferent activity by percutaneous, catheter-based endovascular radiofrequency ablation effectively lowers BP, a recent clinical trial did not observe a significant effect on SBP in patients with resistant HTN. 59 Furthermore, there was controversial or inconsistent evidence concerning the improvement of hyperglycemia, obesity, and dyslipidemia through RSND. [60] [61] [62] [63] In contrast, most clinical studies, including ours, have shown that metabolic surgery had a satisfying outcome in regard to weight loss, remission of hyperglycemia, and improvement of dyslipidemia. 64 Obesity, T2DM, and obstructive sleep apnea syndrome are common causes of resistant HTN. Thus, metabolic surgery might be a novel option for the management of resistant HTN, especially for hypertensive patients with the complications of obesity and T2DM. 65 In summary, we demonstrate that metabolic surgery treatment lowers BP in hypertensive patients and genetic hypertensive rats. Our mechanistic evidence suggests that this CV benefit is likely to be the result of decreasing excessive sympathetic activation. Our findings provide insights into the mechanism of metabolic surgery in the regulation of BP. GI intervention may represent a promising intervention in resistant hypertension with metabolic disturbances.
